Clinical trial · Observational
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
NCT06055764CI-TRIAL-00070031not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Role of FDG PET/CT in patients with metastasis of unknown origin. Role of FDG PET/CT in patients with metastasis of unknown origin.
- timeFrame
- through study completion an average 2 years
- description
- patients with metastasis of unknown origin will do PET/CT searching for primary and find if it will change management or not Procedure: All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital. PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or * Patients with clinico-radiological suspicious of having metastases. Exclusion Criteria: * • Age below 18 years, * patients with pathologically proved primary tumor, * Patients suffering from advanced disease and in-cooperative patients. * Pregnant and lactating women. * Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.
References
Publications (2)
- BACKGROUNDPark JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes. 2011 Mar 9;4:56. doi: 10.1186/1756-0500-4-56. PMID 21385465
- BACKGROUNDKwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17. PMID 18925401